Live
FierceBiotechUniQure stock surges after FDA U-turn clears path to gene therapy filingPharmaVoiceWhy ivermectin is in the limelight againClinical OMICsPhilippe Pouletty: Turning Europe’s Life Science Startups Into World LeadersLabiotechEight in vivo CAR T biotechs to follow closelyFierceBiotech'Biopharma ecosystem is back to full health,' fueled by M&A: PwCFierceBiotechJazz, AbCellera strike TCE discovery and development deal worth up to $792M per drugEndpoints NewsJazz turns to AbCellera for T cell engagers in up to $4.1B partnershipEndpoints NewsSpot Bio launches with $40M to study mRNA therapy for muscular dystrophyEndpoints NewsTriveni Bio raises $65M ahead of upcoming readouts on eczema drugsCellCellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathologyCellA CRISPR knockout mouse library for functional genomics in influenza researchEndpoints NewsMigraine biotech Vedana Therapeutics makes its debut with $46M Series A
FierceBiotech Jan 29, 2026

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Original
Body unavailable. Use the original source.